Amperos, an AI-native revenue cycle management platform, has raised $16M in Series A funding led by Bessemer Venture Partners. The company automates denial management and insurance collections through its multi-modal AI coworker Amanda. The capital will fuel product expansion and hiring across sales, engineering, and operations.
Denial Crisis Drives RCM Investments
The raise arrives as claim denial rates reach 12% of submitted claims, costing providers $262B annually in lost revenue, per industry data. RCM staffing shortages affect 63% of teams with 32% turnover rates per Amperos. Competitors like AKASA have raised $258M for broader RCM automation, while Thoughtful AI secured $35M. Amperos differentiates with agentic AI handling end-to-end workflows from portals to phone calls.
$262B Losses Fuel Urgency
Healthcare providers lose $260B yearly to denials, with recovery efforts costing another $26B, according to Bessemer. Payer audits have risen 12-14% in 2025, pushing denial rates to record highs per Fierce Healthcare. Traditional manual processes fail amid labor shortages, leaving 70% of appeals unresolved.
Amanda Automates Full Workflow
Amperos' Amanda integrates across insurance portals, phone calls, and appeals, reasoning across modalities for 22% higher recovery per claim at 50% lower cost versus legacy methods. Unlike coding-focused tools like CodaMetrix, Amanda targets downstream collections and complex denials. The platform deploys day-one without lengthy setup, already serving 3,000+ locations across 50 states and recovering $700M in revenue annually.
As Sofia Guerra, Partner at Bessemer Venture Partners, noted:
"Denials are one of healthcare's fastest-growing pain points."
Bessemer Backs Agentic AI Shift
Bessemer led the round with participation from Uncork Capital and Neo, following Amperos' $4.2M seed in June 2025. This investor mix signals conviction in AI agents for regulated healthcare workflows, aligning with Bessemer's thesis on tackling massive RCM inefficiencies. The funding validates Amperos' traction post its prior seed.
RCM Market Scales to $273B
The U.S. RCM market stands at $141.61B in 2024, projected to reach $272.78B by 2030 at 11.55% CAGR per Arizton. AI-driven segments grow faster at 24.19% CAGR to $219.48B by 2035. Peers like Sift Healthcare ($30M+) focus on payments, while Amperos owns denial recovery.
Founders Blend Healthcare, Tech Expertise
CEO Michal Miernowski brings 8+ years in healthcare private equity from Goldman Sachs, Onex, and Ardea Partners. CPO Alvin Wu led products at Samsara and Fitbit (Google), while CTO Wilson Wang engineered at Amazon and founded AI chatbot SupportChat. This mix equips Amperos to scale AI in compliance-heavy RCM.
Valerie DeCaro, VP RCM at DOCS Dermatology, noted:
"Our partnership with Amperos has helped ease the workload… we've been able to recover 24% more claims without increasing headcount."
Hiring Spree Powers National Expansion
Post-Series A, Amperos hired SVP Sales Scott Turkow (ex-Scale AI, Medallion), Head of RCM Services DeCiembre D. White (ex-Hospital for Special Surgery), and others in engineering and ops. Partnerships with U.S. Urology Partners (200+ providers) and Boulder Care expand reach. The team eyes further growth beyond current 3,000+ clinics.